\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{The Human Genome Revolution}{section.1.1}% 3
\BOOKMARK [3][-]{section*.4}{The First Human Genome Sequence}{subsection.1.1.1}% 4
\BOOKMARK [3][-]{section*.5}{Expectations of Genomics}{subsection.1.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.2}{Technologies to Enable Genetics Research}{section.1.1}% 6
\BOOKMARK [3][-]{section*.6}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.2}% 7
\BOOKMARK [3][-]{section*.7}{Microarrays and Quantitative Technologies}{subsection.1.1.2}% 8
\BOOKMARK [3][-]{section*.8}{Massively Parallel ``Next Generation'' Sequencing Technologies}{subsection.1.1.2}% 9
\BOOKMARK [4][-]{section*.9}{Established Sequencing Technologies}{section*.8}% 10
\BOOKMARK [4][-]{section*.10}{Emerging Sequencing Technologies}{section*.8}% 11
\BOOKMARK [3][-]{section*.11}{Bioinformatics as an Interdisciplinary Approach to Genomics Data}{subsection.1.1.2}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.4}{Cancer Genomes}{section.1.1}% 14
\BOOKMARK [3][-]{section*.12}{The Cancer Genome Atlas Project}{subsection.1.1.4}% 15
\BOOKMARK [3][-]{section*.13}{The International Cancer Genome Consortium}{subsection.1.1.4}% 16
\BOOKMARK [3][-]{section*.14}{Sub-population and Cell Line projects}{subsection.1.1.4}% 17
\BOOKMARK [2][-]{subsection.1.1.5}{Genomic Cancer Medicine}{section.1.1}% 18
\BOOKMARK [3][-]{section*.15}{Cancer Genes and Driver Mutations}{subsection.1.1.5}% 19
\BOOKMARK [3][-]{section*.16}{Personalised or Precision Cancer Medicine}{subsection.1.1.5}% 20
\BOOKMARK [4][-]{section*.17}{Molecular Diagnostics and Pan-Cancer Medicine}{section*.16}% 21
\BOOKMARK [3][-]{section*.18}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.5}% 22
\BOOKMARK [4][-]{section*.19}{Targeting Oncogenic Driver Mutations}{section*.18}% 23
\BOOKMARK [4][-]{section*.20}{ Network Medicine, and Polypharmacology}{section*.18}% 24
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 25
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 26
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 27
\BOOKMARK [2][-]{subsection.1.2.3}{Studies of Synthetic Lethality}{section.1.2}% 28
\BOOKMARK [3][-]{section*.22}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 29
\BOOKMARK [4][-]{section*.23}{Conservation and Evolution of Synthetic Lethality}{section*.22}% 30
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethal Concepts in Cancer}{section.1.2}% 31
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 32
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 33
\BOOKMARK [3][-]{section*.25}{Examples of High-throughput Synthetic Lethal Screens}{subsection.1.2.6}% 34
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 35
